Ubs Group Ag Titan Pharmaceuticals Inc Transaction History

Ubs Group Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.26 - $0.48 $0 - $0	-2 Reduced 50.0%	2 $0
Q3 2023 Nov 09, 2023	BUY	$0.45 - $0.66 $1 - $2	4 New	4 $0
Q1 2023 May 12, 2023	BUY	$0.73 - $1.05 $993 - $1,429	1,361 Added 824.85%	1,526 $1,000
Q4 2022 Feb 08, 2023	SELL	$0.77 - $22.8 $8,478 - $251,050	-11,011 Reduced 98.52%	165 $0
Q3 2022 Nov 10, 2022	SELL	$0.53 - $22.6 $8,357 - $356,379	-15,769 Reduced 58.52%	11,176 $12,000
Q2 2022 Aug 10, 2022	BUY	$0.38 - $0.94 $7,532 - $18,632	19,822 Added 278.28%	26,945 $15,000
Q1 2022 May 16, 2022	BUY	$0.89 - $1.26 $2,959 - $4,189	3,325 Added 87.55%	7,123 $7,000
Q4 2021 Feb 14, 2022	SELL	$1.02 - $1.93 $3,361 - $6,361	-3,296 Reduced 46.46%	3,798 $4,000
Q3 2021 Nov 15, 2021	SELL	$1.87 - $2.57 $2,202 - $3,027	-1,178 Reduced 14.24%	7,094 $13,000
Q2 2021 Aug 13, 2021	SELL	$2.24 - $2.9 $34,018 - $44,042	-15,187 Reduced 64.74%	8,272 $22,000
Q1 2021 May 12, 2021	BUY	$2.66 - $4.23 $46,276 - $73,589	17,397 Added 286.98%	23,459 $70,000
Q4 2020 Feb 11, 2021	BUY	$3.0 - $6.0 $18,186 - $36,372	6,062 New	6,062 $20,000

Ticker TTNP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,629,200
Market Cap $49.4M
Description
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the Euro...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.